Labiotech.eu

News and Trends 1 Aug 2017

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems

AiCuris’ Pritelivir has now secured FDA endorsement in the form of a Fast Track Designation in immuno-compromised patients. Based in Wuppertal, Germany, and spun out from Bayer, AiCuris is focused on curing infectious diseases. Its lead candidate for herpes simplex viruses 1 and 2 (HSV-1 and -2), pritelivir, has been watched closely for its promise […]

August 1, 2017 - 2 minutesmins - By Editorial Team

News and Trends 28 Jul 2017

Things are Looking Up for UK Synbio Clusters, says Report

A survey of synbio startups in the last 16 years shows that the UK ecosystem is growing rapidly and approaching critical mass, says SynbiCITE. Dedicated to championing industrial uptake of synthetic biology, SynbiCITE is a knowledge center based at Imperial College London. Some of its initiatives have included opening a gene foundry last year to providing grants to […]

July 28, 2017 - 3 minutesmins - By Denise Neves Gameiro

Cancer immunotherapy resistance mechanism University Hospital Zurich

News and Trends 27 Jul 2017

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

astrazeneca imfinzi durvalumab tremelimumab

News and Trends 27 Jul 2017

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

AstraZeneca has announced its Phase III trial with durvalumab and tremelimumab has failed to achieve better results than standard chemotherapy in lung cancer. AstraZeneca’s MYSTIC study was evaluating a combination of checkpoint inhibitors as a first-line treatment for metastatic non-small cell lung cancer. The therapy couldn’t improve progression-free survival when compared with the standard of care […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

CureVac mrna vaccine rabies Ingmar Hoerr

News and Trends 26 Jul 2017

German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine

CureVac has published proof-of-concept data for an mRNA rabies vaccine that could open the door for a new generation of better and cheaper vaccines. CureVac, based in Tübingen, Germany, is a pioneer in the development of therapeutic mRNA technology. The company has published today in The Lancet proof-of-concept data from a Phase I trial testing CV7201, […]

July 26, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jul 2017

Dutch Biotech Reports Positive Phase II Data on Rare Inflammatory Disease

Pharming has published Phase II data in The Lancet supporting its lead candidate as a treatment for the rare genetic disease hereditary angioedema. Pharming, one of the top biotechs in Leiden, specializes in recombinant protein technology. Its lead compound, ruconest, is a recombinant human C1 inhibitor protein. The results of a 32-patient Phase II study published […]

July 26, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 26 Jul 2017

Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb

Update (26/07/2017): Verona Pharma has dosed the first patients in the PhaseIIb with RPL554 in patients with chronic obstructive pulmonary disease (COPD). Results are expected in the second half of 2018. Published on 27/06/2017 Verona Pharma has secured regulatory approval in five European countries to run a Phase IIb trial with its dual PDE3/4 inhibitor in […]

July 26, 2017 - 2 minutesmins - By Melanie De Almeida

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […]

July 25, 2017 - 6 minutesmins - By Evelyn Warner

More News! 24 Jul 2017

Bayer and Evotec Extend their Endometriosis Partnership

Bayer and Evotec have decided to extend their partnership for the development of endometriosis drugs now that their second candidate has made it to Phase I. Bayer and Evotec have announced today that a second compound derived from their endometriosis partnership has made it to clinical trials. The team has decided to extend the partnership […]

July 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 24 Jul 2017

How can Recombinant Proteins be used in Veterinary Medicine?

This expert has told us why recombinant proteins are an elegant way to go in the production of veterinary vaccines and why glycosylation patterns can play a big part in all of it! For many decades, human blood plasma has been a source of different biotherapeutic proteins, including antibodies, albumin and blood coagulation factors. Although they are […]

July 24, 2017 - 5 minutesmins - By External Contributor

Francis Crick institute Veronique Birault Head of Translation

Interview 24 Jul 2017

Discussing Open Science with the Head of Translation at The Francis Crick Institute

Officially opened less than a year ago, The Francis Crick Institute is already conducting top-level biomedical research, has launched two spin-outs and struck research partnerships with both AstraZeneca and GlaxoSmithKline. I spoke to the Head of Translation, Dr. Véronique Birault, to learn more about the Crick’s unique model of translation and the key for its […]

July 24, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Jul 2017

Roche Abandons Spanish Cancer Epigenetics Drug

Roche has decided to terminate its license agreement with Spanish biotech Oryzon Genomics after rearranging its portfolio priorities. Oryzon Genomics, a biotech based in Barcelona working on epigenetics, was notified yesterday by Roche about the discontinuation of their deal concerning the biotech’s lead candidate, ORY-1001. Roche announced the decision was not based on clinical data, […]

July 21, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems

Things are Looking Up for UK Synbio Clusters, says Report

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

AstraZeneca Misses Endpoint in Big Checkpoint Inhibitor Combo Trial

German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine

Dutch Biotech Reports Positive Phase II Data on Rare Inflammatory Disease

Update: Potential Breakthrough Treatment for Deadly Lung Disease Starts Phase IIb

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Bayer and Evotec Extend their Endometriosis Partnership

How can Recombinant Proteins be used in Veterinary Medicine?

Discussing Open Science with the Head of Translation at The Francis Crick Institute

Roche Abandons Spanish Cancer Epigenetics Drug

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!